BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CryoTherapeutics GmbH Completes Second Closing of Series A Financing Round With a Total Volume of EUR 3 Million and Adds Charite Biomedical Fund as Investor


3/21/2013 9:53:50 AM

COLOGNE, GERMANY--(Marketwire - March 21, 2013) - CryoTherapeutics GmbH (CryoTherapeutics), the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease, announced today that it has completed a second closing of its Series A financing round, with Peppermint VenturePartners (PVP) via its new Charité Biomedical Fund joining the investor consortium. The additional investment by PVP is in addition to the Series A financing round closed in June 2012 by NRW.BANK, High-Tech Gründerfonds (HTGF), private investor Rainer Christine and Getz Brothers bringing the total of the Series A round to EUR 3 million.

CryoTherapeutics was established in December 2009 in Germany by a team of experienced serial entrepreneurs from the UK, US and Canada and is focusing on developing a novel catheter system, which utilizes cryoenergy to treat and prevent heart attacks. The initial objective of the Company is the demonstration of the clinical benefit in the treatment of heart attack patients using this catheter-based system that will be utilized by interventional cardiologists.

Maurice Buchbinder, MD, founder and Chief Medical Officer of CryoTherapeutics, stated: "Given the potential anti-inflammatory effect of cryoenergy in the vascular region, particularly when applied to vulnerable or ruptured plaque, cryotherapy in the setting of heart attack may stabilize the culprit lesion promoting optimal healing."

John Yianni, PhD, founder and Managing Director, commented: "This expansion of our Series A financing enables CryoTherapeutics to accelerate the completion of the cryosystem for demonstrating the safety of this new treatment option for heart attack patients in a first-in-man study."

Kay Balster, Investment Manager at HTGF, said: "We are pleased that we could work with CryoTherapeutics to attract an experienced consortium of investors to advance this exciting technology into the clinical stage. We are also delighted that PVP has joined the consortium thus recognizing the progress in the technical development as well as the accomplishments of the management team."

Joachim Rautter, Managing Partner at PVP, added: "CryoTherapeutics offers a new therapy option for interventional cardiologists to treat unstable atherosclerotic plaques, which presents an exciting market opportunity. An additional asset is a founder team of serial entrepreneurs with a successful track record in the international MedTech industry in recent years."

About Peppermint VenturePartners: PVP is a Berlin-based venture capital company investing in young healthcare companies with a focus on medical devices, mainly within Europe, that have successfully demonstrated a first proof-of-concept for their technology, product or services. At the end of 2010 PVP, in association with the Charité Foundation, launched the new Charité Biomedical Fund (CBF). In the framework of its established collaboration with the Charité - Universitätsmedizin Berlin, PVP has access to the proprietary network and evaluation platform of one of the largest medical schools in Europe and to its international partners. PVP currently manages funds exceeding EUR 50 million.

About CryoTherapeutics GmbH: CryoTherapeutics was established in December 2009 in Potsdam by a team of serial entrepreneurs from the UK, US and Canada with initial seed funding by HTGF, the founders and two private investors. The focus of the company is the development, demonstration of clinical benefit, and early-stage commercialization of cryotherapy systems for the treatment of coronary plaque. In the course of the Series A financing the company has moved to Cologne as it enters its clinical development stage.

About High-Tech Gründerfonds: High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gründerfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has approximately EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II). Please visit www.high-tech-gruenderfonds.de for more information.


Contact:
Peppermint VenturePartners GmbH
Dr. Joachim Rautter
Managing Partner
Kurfurstendamm 21
10719 Berlin / Germany
Phone: +49 30 590064 411
E-Mail: jr@peppermint-vp.com
Homepage: www.peppermint-vp.com

Contact:
CryoTherapeutics GmbH
Dr. John Yianni
Managing Director
Gottfried-Hagen Str. 62
51105 Koln / Germany
Telephone: +49 174 3210214
E-Mail: jy@cryotherapeutics.com
Homepage: www.cryotherapeutics.com

Contact:
High-Tech Grunderfonds Management GmbH
Kay Balster
Investment Manager
Schlegelstrasse 2
53113 Bonn
Phone: +49 (0)228 823001-00
Fax: +49 (0)228 823000-50
Email: k.balster@htgf.de
Internet: www.high-tech-gruenderfonds.de



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES